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Abstract
Background—Results of previous studies suggest that β-adrenoreceptor activation may augment 
pain, and that β-adrenoreceptor antagonists may be effective in reducing pain, particularly in 
individuals not homozygous for the catechol-O-methyltransferase (COMT) high activity 
haplotype.
Methods—Consenting patients admitted for thermal burn injury at participating burn centers 
were genotyped; those who were not high activity COMT homozygotes were randomized to 
propranolol 240mg/day or placebo. Primary outcomes were study feasibility (consent rate, 
protocol completion rate) and pain scores on study days 5-19. Secondary outcomes assessed pain 
and posttraumatic stress disorder (PTSD) symptoms 6 weeks post-injury.
Results—Seventy-seven (61/79) percent of eligible patients were consented and genotyped, and 
77% (47/61) were genotype-eligible and randomized. Ninety-one percent (43/47) tolerated study 
drug and completed primary outcome assessments. In intention to treat and per protocol analyses, 
patients randomized to propranolol had worse pain scores on study days 5-19.
Conclusions—Genotype-specific pain medication interventions are feasible in hospitalized burn 
patients. Propranolol is unlikely to be a useful analgesic during the first few weeks after burn 
injury.
Keywords
propranolol; burn; randomized control trial; catechol-O-methyltransferase
Introduction
More than 700,000 individuals seek care for burn injury in the United States each year, and 
more than 50,000 require hospitalization.1 Even with currently available medications, 
moderate or severe pain after burn injury is common and remains a substantial clinical 
challenge.2,3 New medication treatments which target novel mechanisms are needed in order 
to reduce the suffering of patients with major burn injury.4
Results of both preclinical and clinical studies suggest that β-adrenoreceptor activation may 
contribute to hyperalgesia and allodynia. In animal models, catecholamines induce 
hyperalgesia and allodynia via β2- and β3- adrenoreceptor stimulation5,6, and this enhanced 
pain sensitivity can be prevented by the administration of the nonselective β-adrenergic 
antagonist propranolol.7,8 In human observational studies, genetic variants in the gene 
coding for the β2-adrenoreceptor (ADRB2) have been found to be associated with 
vulnerability to develop pain conditions.9,10,11 In a case-crossover study of propranolol 
treatment for patients with chronic musculoskeletal pain (n = 40), more patients reported a 
reduction in pain during propranolol treatment.12 Participants in that study were also 
genotyped at the gene coding for the enzyme catechol-O-methyltransferase (COMT), the 
primary enzyme that metabolizes catecholamines.13 When stratified by common COMT 
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haplotypes, a beneficial effect of propranolol on pain was found among participants not 
carrying a high activity COMT haplotype.12 (Individuals without a high activity COMT 
haplotype have less COMT enzyme activity and relatively high synaptic catecholamine 
levels.14) A diminished benefit of propranolol on pain was observed in COMT high activity 
haplotype heterozygotes, and no benefit was noted among homozygotes.12
Based on these results, we hypothesized that propranolol administration would reduce pain 
severity in patients hospitalized with major thermal burn injury who were not homozygous 
for the high activity COMT haplotype. We performed a pilot randomized double-blind 
clinical trial to (1) assess the feasibility of performing a genotype-based multisite trial in 
patients with major thermal burn injury and (2) evaluate the potential efficacy of propranolol 
in reducing pain in burn patients without a high activity COMT haplotype.
Materials and Methods
This was a pilot genotype-based, multisite, double-blind randomized clinical trial. Local 
Institutional Review Board (IRB) approval was obtained from study site IRBs (University of 
North Carolina IRB, Chapel Hill, NC; MedStar Health Research Institute IRB, Washington, 
DC; Wake Forest University Health System IRB, Wake Forest, NC; Crozer-Keystone 
Health System IRB, Upland, PA). Written informed consent was obtained from all subjects. 
Participant safety data was monitored quarterly by the University of North Carolina Data 
Safety Monitoring Board (DSMB). Participant recruitment occurred between June 2009 and 
January 2011.
Eligibility Criteria
Individuals admitted to participating burn centers within 72 hours of sustaining a thermal 
burn injury involving ≤20% total body surface area (TBSA) were eligible for study 
participation. Patients with major burns >20% were deemed too critically ill for this study. 
Exclusion criteria also included an estimated hospital stay at the time of admission of <5 
days or >40 days, intentional injury, substantial concomitant non-burn injury, and greater 
than first degree cardiac conduction blockade. Patients who were already taking a β-
adrenergic antagonist medication or who were non-English speaking, clinically unstable, a 
prisoner, or who had a history of asthma, diabetes, coronary artery disease, psychotic 
disorder, or hepatic, renal, or congestive heart failure were also excluded. Also ineligible 
were patients whose highest pain score between admission and recruitment was < 4 (0-10 
numeric rating scale (NRS)) or who were on opioid medications for chronic pain prior to 
their burn injury.
Study Procedures Prior to Randomization
All admitted burn patients were screened for potential eligibility via hospital electronic 
records; potentially eligible patients were approached by research staff for participation 
within 48 hours of admission. Blood samples for genotyping were collected from consenting 
patients via EDTA Vacutainer collection tubes (BD, Franklin Lakes, New Jersey, USA). 
DNA was subsequently purified from these samples using QIAamp DNA Mini Kit (Qiagen, 
Valencia, California, USA). Genotyping at rs4818 was performed on study day 1 or 2 using 
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the TaqMan Assay on a Bio-Rad CFX96 Real-time PCR Detection System (Bio-Rad, 
Hercules, California, USA). SNP rs4818 was used to identify the high activity COMT 
haplotype, because a C genotype at rs4818 identifies the high activity COMT haplotype with 
approximately 95% accuracy.14
Randomization
A computer generated protocol created a numbered sequence of treatment assignments 
(allocation list) at each study site using permuted blocks (block sizes of 2 and 4) stratified by 
race (European American, African American, or other) and sex. On study day three, study 
participants who were not homozygous for the high activity COMT haplotype were 
randomized to propranolol hydrochloride or placebo using the allocation list at their study 
site.
Blinding Procedures
Other than the study biostatistician, all burn unit staff, research data collectors, and 
investigators were blinded to randomization schedule. Investigational drug pharmacy 
personnel at each study site maintained the unblinded study site allocation list and assigned 
participants to treatment arm. Capsules (sight, taste, smell) and medication bottles were 
identical across treatment arm. Bottles were marked by unique study ID numbers only. 
These methods were used to help ensure that if a single patient was unblinded (for whatever 
reason), the entire study would not be unblinded.
Dosing, Escalation, and Taper of Study Medication
Propranolol hydrochloride is used routinely in adults at doses of 240-320mg/day for 
indications such as migraine prophylaxis15,16 and essential tremor17-19 and has been used 
safely in burn patients to decrease the metabolic consequences of burn injury.20-22 Based on 
this safety profile and lack of established dose regimen for burn pain, a dose of 120mg BID 
of propranolol (240mg/day) was selected for patients receiving active study drug. 
Propranolol hydrochloride extended release capsules (Par Pharmaceuticals) were used, 
because this formulation has been rated by the FDA as bioequivalent to Inderal LA.23
Following randomization, study participants received an initial test dose of 40mg of short-
acting propranolol or placebo on study day three. Heart rate and blood pressure were 
assessed 30 and 60 minutes after test dose administration, and participants were observed by 
study personnel for at least one hour for potential adverse events. After test dose 
administration, participants received study drug (propranolol 60mg ER or placebo capsules) 
according to the following schedule: one capsule BID × two doses, then two capsules BID 
until three weeks following hospital discharge, and then a 20 day taper. This 20 day study 
drug taper consisted of two capsules in the AM and one in the PM for 5 days, one capsule in 
the AM and one in the PM for 5 days, one capsule in the AM for 10 days, and then 
discontinuation.
Evaluation of Participant Adherence
During hospitalization study drug was administered by burn center nurses along with other 
medications. After discharge, adherence to the study medication was assessed via child-
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resistant Medication Event Monitoring System (MEMS) medication bottle caps.24 These 
caps contain an electronic microcircuit chip which records each date and time that a pill 
bottle is opened. After completion of the study taper, participants were asked to return their 
pill bottle with MEMS cap via a postage-paid container supplied by the study team. MEMS 
cap data were then downloaded to a desktop computer using MEMS software (Powerview, 
Aardex Ltd, Zug, Switzerland), and the percent of standard doses taken as prescribed (BID) 
and the percentage of days at least one dose was taken were calculated. Consistent with 
previous studies, for sensitivity analyses “adherent” patients were defined as those with ≥ 
80% of prescribed doses removed from the MEMS device according to protocol.25
Participant Assessments
Participant demographic information (e.g. education, income), baseline pain measures, and 
distress symptoms (Peritraumatic Distress Inventory26) were assessed during initial 
interview evaluation. During hospitalization study participants received daily assessments 
evaluating adverse events and pain severity (waking, worst, least, and average pain severity 
during the past 24 hours). Each pain severity assessment was performed using a 0-10 NRS. 
NRS scales are a valid method of assessing pain27 and have advantages in burn patients who 
often are unable to record visual analogue scale responses due to upper extremity injuries.
Following discharge, study participants continued to receive the same adverse event and 
pain severity assessments via telephone on study days 5, 7, 10, 13, 17, and 19. Between 
study day 19 and the beginning of the patient's taper, subjects received adverse event 
assessments twice a week if in the hospital and once a week if outpatient. All patients also 
completed a structured six week outcome evaluation via telephone or in-person interview. 
This evaluation included an assessment of waking, worst, and least pain intensity (0-10 
NRS) and an assessment of posttraumatic stress disorder (PTSD) symptoms (Posttraumatic 
Symptom Scale - Interview Version28 (PSS-I)) during the past week. Participants were paid 
$50 for completing this six week follow-up assessment.
Primary Outcomes
Primary study outcomes were study feasibility and acute pain differences between treatment 
arms. Consent and protocol completion rates were selected prior to study start as main study 
feasibility outcomes (consent rate, protocol completion rate). Average pain scores during the 
past 24 hours on study days 5, 7, 10, 13, 17, and 19 were selected prior to study start as 
primary acute pain outcomes. However, soon after starting the study it was observed that 
patients sometimes provided an “average” pain rating greater than their worst reported pain 
or less than their least reported pain. These observations, together with the high degree of 
educational disadvantage in this population, led us to appreciate that our interview question 
regarding “average pain” was poorly designed for the study population and did not reliably 
yield valid data. We therefore used linear mixed modeling to combine the pain 
measurements assessed from all participants on primary outcome days (waking, worst and 
least pain) into an “overall pain” score for each of these days. This alternative primary acute 
pain outcome was defined after the study start and prior to study analyses (secondary 
analyses also evaluated our original primary outcome measure, average pain severity). A 
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reduction of two or more points (on a 0 - 10 NRS) was considered the threshold for a 
clinically relevant improvement in pain.29
Secondary Outcomes
Secondary analyses assessed for the potential evidence of propranolol efficacy in several 
other domains. Because β-adrenoreceptor blockade may influence risk of persistent pain 
development, pain severity six weeks after study enrollment between study groups was 
assessed using ANOVA tests. Also, because some studies30-33 (but not others34,35) suggest 
that propranolol may reduce PTSD symptoms, PTSD symptom severity and diagnosis 
(based on PSS-I criteria36) six weeks after enrollment were also assessed. Finally, as 
described above, secondary analyses examined primary study outcomes using our average 
pain measure.
Sample Size Estimation
At the time of study design, there was little information with which to generate sample size 
estimates. The most applicable data came from a report of pain scores after median 
thoracotomy among patients randomized to a beta-antagonist vs. placebo.37 Based on these 
data, and our use of repeated measures within each subject, we felt that randomization group 
sizes of n = 20 (total n = 40) would be sufficient to assess study feasibility and to generate 
useful estimates of potential propranolol efficacy.
Statistical Analyses
To evaluate study feasibility, descriptive statistics were used to evaluate consent and 
protocol completion rates. Outcomes of patients randomized to propranolol vs. placebo 
through study day 19 were compared using repeated measures (or correlated outcomes) 
analysis. The following model was used: Yij = β0 + β1×treatment + β2×day + (β1β2)
×treatment×day + eij, where Yij is the overall pain score for subject i on day j; β0 is the 
intercept; β1 is the main effect for treatment (propranolol vs. placebo), β2 is the time effect 
(change in pain scores over time), (β1β2) is the treatment x time interaction coefficient, and 
eij is the random error associated with measurement of the ith subject on the jth day. Missing 
patient data were not included in the model. The correlation among measures within each 
subject was taken into account by the covariance structure of the random errors, using 
generalized estimating equations (GEE)38. After fitting the model, the significance of the 
interaction term (β1β2) was assessed. If significant, it would mean that the effect of treatment 
on pain trajectory slope varies by time. Six week pain and PTSD symptoms according to 
treatment group were compared using the following ANOVA model: Yi = β0 + β1×treatment 
+ ei, where Yi is the pain score assessed in the ith subject at week 6; β0 is the intercept; β1 is 
the main effect for treatment (propranolol vs. placebo), and ei is the random error associated 
with the measurement on the ith subject.
Ninety five percent confidence intervals around observed treatment group differences in 
intention to treat, per protocol, and adherent patient analyses were obtained using the above 
model. For the purposes of graphic data representation, the model was modified to treat the 
time variable as categorical. Least square means of overall pain scores (combining waking, 
worst and least pain) were obtained for each day by treatment group, together with standard 
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errors of the mean. All analyses were conducted using SAS (version 9.2, SAS Institute Inc., 
Cary, NC). P-values < .05 were considered statistically significant.
Results
Enrollment and feasibility assessments
Most patients (766/845, 91%) did not meet the relatively strict eligibility criteria (designed 
to limit potential adverse events) in this proof of concept trial (Figure 1). The most common 
reasons for exclusion were non-thermal burn injury, age > 60 years, and hospital admission 
> 72 hours after burn. Of those meeting initial eligibility criteria, 61 (77%) consented. 
Among those providing initial consent, 12 (20%) were genotype ineligible and 2 (3%) were 
withdrawn before randomization. Twenty-three participants were randomized to the 
propranolol arm and 22 participants received the intervention (one refused further 
participation after randomization but before receiving the study medication). Twenty-four 
participants were randomized to placebo and 23 received the intervention (one refused 
further participation after randomization but before receiving the study medication). Two 
participants (9%) in the propranolol arm dropped out after randomization (during dose 
escalation) due to adverse events (nausea). The final numbers of patients who completed the 
primary outcome assessments for intention to treat analysis was 20 patients receiving 
propranolol and 23 patients receiving placebo. However, during the study one patient 
assigned to the placebo group erroneously received propranolol. Thus, for the per protocol 
analysis, the number of patients in the propranolol and placebo groups were 21 and 22, 
respectively.
Characteristics of the 43 participants are shown in Table 1. Most patients were young 
European American males, had some education past high-school, and had suffered a partial 
thickness burn that was ≤ 10% TBSA (average TBSA ∼6%). Median annual family income 
reported by study participants was $20,000-39,000. Baseline clinical characteristics of 
patients in the two treatment groups were similar. On Day 1, mean pain scores in both arms 
were close to 6. Dressing changes were performed daily on all in-hospital patients except 
during post-operative days 1-3, during which time patients' dressings were irrigated 
regularly.
Evaluation of Participant Adherence
Median length of hospital stay was 11 days (range 3 - 41 days). All study participants were 
adherent during hospitalization, when their study medication was administered by a hospital 
nurse. Adherence following discharge (determined via analysis of Medication Event 
Monitoring System (MEMS) data) is shown in Table 2. Participants in the placebo arm 
tended to have higher rates of adherence in terms of both the percentage of days the correct 
dose was taken (p=.189) and the percentage of days at least one dose was taken (p=.137).
Primary Outcomes
The effects of propranolol on overall pain score by treatment arm are shown in Figure 2. 
Patients randomized to propranolol had slightly worse overall pain outcomes across the 
primary assessment period. The 95% confidence intervals around observed treatment group 
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differences in overall pain in intention to treat, per protocol, and adherent patient analyses 
did not include a clinically relevant treatment benefit for propranolol (Table 3). Outcomes 
for average pain over time were very similar to results for overall pain (Table 3). In per 
protocol and intention to treat analyses, there was a statistically significant (but clinically 
non-meaningful) worsening of average pain scores in the propranolol vs. the placebo groups.
Secondary Outcomes
There was no significant difference in opioid use during hospitalization between 
randomization arms (average morphine equivalent dose per day 68.1±14.1 in patients 
randomized to propranolol vs. 77.4±12.6 in patients randomized to placebo, p=.63). Follow-
up data to assess secondary outcomes assessing the effects of propranolol at six weeks were 
available for 38/43 (88%) of randomized patients (16/20 (80%) patients randomized to 
propranolol and 22/23 (96%) patients randomized to placebo). Comparison of six week 
overall and average pain scores according to treatment group are shown in Table 4. Point 
estimates for overall pain were lower for propranolol patients in per protocol, intention to 
treat, and adherent analyses. Confidence intervals around point estimates for overall pain did 
not include a clinically relevant treatment effect. Comparison for average pain differences at 
6 weeks are also shown in Table 4. Confidence intervals for average pain included a 
clinically relevant treatment effect for adherent patients, but not for per protocol or intention 
to treat analyses. There was a non-significant reduction in PTSD symptoms (PSS-I score 
8.1±11.4 vs. 10.7±13.1, p = .51) among patients randomized to propranolol vs. control, as 
well as a non-significant reduction in the percentage of patients who met criteria for PTSD 
diagnosis (3/17 (19%) vs. 6/22 (27%), p = .71).
Adverse Events
Table 5 presents adverse events according to treatment arm. No significant differences were 
observed in the number of events between treatment groups. The most common side effects 
in the control arm were gastrointestinal and dermatologic (6 cases each). The most common 
side effect in the treatment arm was metabolic/laboratory (11 cases).
Discussion
Our results support the feasibility of performing clinical trials of pain medications in a 
genotype-selected subgroup of patients with major thermal burn injury. Seventy seven 
percent of eligible patients consented to the protocol, and 91% of randomized patients 
tolerated study drug and completed primary outcome assessments. Overall medication 
adherence after discharge from the burn unit (median length of stay 11 days) was relatively 
poor, even compared to other electronic monitoring adherence studies, which have found 
that patients are only adherent to BID medications on 70-80% of study days.39-41 Patients 
randomized to propranolol tended to be less adherent than placebo patients (adherent with 
one or more doses on 70% vs. 86% of study days, BID adherence on 48% vs. 62% of study 
days). This trend towards decreased adherence in the propranolol group may be due to 
increased side effects and/or a lack of pain relief efficacy.42-45 The overall reduced 
adherence in this study vs. other studies may also be due to the relatively low socioeconomic 
status of the patient population.46,47
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Individuals randomized to propranolol tended to have worse pain scores during the 19 day 
study period. The 95% confidence intervals around observed treatment group differences in 
overall pain (and average pain) in per protocol, intention to treat, and adherent patient 
analyses did not include a clinically relevant treatment effect for propranolol on acute pain. 
In secondary analyses, patients randomized to propranolol had slightly lower overall and 
average pain scores than patients randomized to placebo at six weeks post-burn. Only the 
95% confidence interval for average pain scores among adherent patients included a 
clinically relevant reduction in pain. Patients randomized to propranolol also showed non-
significant reductions in PTSD symptom scores and in the proportion of patients meeting 
criteria for the diagnosis of PTSD.
A challenge to the development of new medications is that large scale clinical trials are 
extremely expensive and require preliminary data, but at the same time the results of small 
preliminary trials may be inaccurate. For this reason, current guidelines recommend that 
small trials focus on confidence intervals rather than point estimates of effect size.48 For 
acute pain during the first 19 days after randomization, the primary outcome of this trial, 
confidence intervals of trial treatment effects did not include a clinically relevant pain 
reduction for propranolol in the selected study population. Similarly, in secondary analyses 
examining the influence of the propranolol intervention on pain symptoms six weeks after 
randomization, confidence intervals of trial treatment effects also did not include a clinically 
relevant reduction in pain, except in a single secondary analysis of average pain scores 
among adherent patients. Together, these findings suggest that propranolol is unlikely to be 
a useful intervention in this patient population.
Tolstoy's famous line, “Happy families are all alike; every unhappy family is unhappy in its 
own way,”49 is applicable to the results of clinical trials. There are a great many different 
reasons that a clinical trial may be negative, including wrong patient population, wrong 
dose, wrong timing of intervention or outcome assessment, wrong (imprecise) assessment 
tool, wrong (unpowerful) study design, or wrong (ineffective) drug. While the results of a 
clinical trial provide little information to distinguish between these possibilities, several 
comments may be useful when considering our results and the available literature.
First, while the etiology of burn pain is unknown, the presence of thermal injury to 
peripheral structures and the quality of patient symptoms suggest a neuropathic 
component.50 A previous case cross-over trial found no evidence of effectiveness with 
propranolol in patients with neuropathic pain51, whereas a trial in patients with a myogenous 
pain disorder suggested a benefit with propranolol in our study population.52 Thus it is 
conceivable that β-adrenoreceptor antagonists in general (or propranolol in particular) are 
more effective in nociceptive than neuropathic pain.
Second, it is possible that our genotype-based eligibility criteria selected a patient population 
less likely to respond to propranolol. In a recent publication using pre-randomization 
observational data from the present trial, we found that patients who are not homozygous for 
the high activity COMT haplotype (patients selected for inclusion in this trial) did indeed 
have higher overall pain scores (6.3 (0.4) vs. 5.4 (0.4), p = .037) during the first two days of 
hospital admission (prior to randomization).53 COMT haplotype was a stronger predictor of 
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overall pain severity among study patients than other factors including burn size or depth.53 
These data suggest that the effect of COMT haplotype on burn pain may occur via 
mechanisms other than via the activation of β-adrenoreceptors, or that this mechanism was 
not effectively modulated with propranolol among the population of burn patients selected 
for inclusion in our study. It is also possible that our genotype-based eligibility criteria were 
too liberal, in that we allowed individuals with one copy of the high activity COMT 
haplotype into the study. Such patients were allowed into the study based on evidence from 
another pain population that patients with one copy of the high activity COMT haplotype 
respond to propranolol.12 We performed secondary analyses evaluating treatment response 
according to high activity COMT haplotype copy number, and found no evidence for an 
effect (non-significant differences (p >.25) and effect size well below a clinically significant 
change in pain (< 1 unit change in 0-10 NRS pain score)). These findings suggest that 
including only patients with no copies of the high activity COMT haplotype would not have 
changed our study results.
Third, it is possible that other, non-genotype-related criteria might identify burn patients in 
the study population who would experience pain relief with propranolol treatment. One 
possibility that we explored in secondary analyses was whether initial cardiovascular 
response to study drug (heart rate or blood pressure response) would predict treatment 
response. Unfortunately, while a reduction in heart rate and blood pressure 60 minutes after 
test dose administration predicted drug response, this was equally true among patients 
receiving propranolol and patients receiving placebo. Thus this reduction is consistent with a 
placebo response rather than a response specifically linked to β-adrenoreceptor antagonism.
Finally, it is possible that propranolol and/or other beta-antagonists would have a therapeutic 
effect only after more prolonged treatment or more long term follow-up assessments. Even 
though patients completed the propranolol intervention prior to the six week follow-up 
assessment, point estimates suggest a more favorable (though marginal) effect of 
propranolol on persistent post-burn pain in comparison with acute burn pain. We do not 
have data past 6 weeks to determine if any more substantive analgesic effect of propranolol 
emerged over time. However, we believe that confidence intervals observed for propranolol 
at 6 weeks, together with the poor observed adherence (and suggestion of differentially poor 
adherence), indicate that propranolol is unlikely to be a useful analgesic in the selected burn 
population during the first months after injury.
In addition to the limitations described above, several other limitations should also be 
considered when interpreting our study results. First, our eligibility criteria limited study 
participation to patients with TBSA burns ≤ 20%, and most patients in our sample had burns 
that were less than 10% TBSA. Study inclusion criteria limited enrollment to patients with 
TBSA burns ≤ 20%, because patients with larger burn injuries are sometimes intubated or 
more heavily sedated, making burn pain assessment difficult, and because patients with 
TBSA burns ≤ 20% constitute the great majority (>86%) of admissions to major burn 
centers.54 It is possible that patients with larger burn injuries, which are associated with 
greater catabolism and hypermetabolism, may have a different analgesic response to 
propranolol intervention. In addition, to reduce the potential risk of study participation, 
patients with greater than first-degree atrioventricular block, patients taking a β-adrenergic 
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antagonist medication, and patients with asthma, diabetes, coronary artery disease, and 
congestive heart failure were excluded from study participation. Therefore the 
generalizability of study findings to these burn patient groups cannot be assessed. Finally, as 
described in the methods section, we erred when we assumed that patients would be 
consistently familiar with the term “average”. Based on responses of initial participants to 
this question, we changed our primary outcome measure to “overall pain”, a combination of 
waking, least, and worst pain. However, as shown above, results for both overall and 
average pain were generally consistent and did not suggest a clinically relevant reduction in 
pain with propranolol intervention. To prevent this error in future burn studies assessing 
symptom outcomes, the term “average” should be avoided in favor of another term (e.g. pain 
“most of the time”).
In conclusion, our study results indicate that genotype-based randomized controlled trials of 
patients with major thermal burn injury are feasible, and that propranolol is unlikely to be a 
useful adjunct to reducing pain during the first months after injury among the population of 
burn patients selected for this study. Further studies are needed to better understand 
mechanisms of post-burn pain and to continue to test interventions to reduce the suffering of 
patients with major thermal burn injury.
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Figure 1. Study Enrollment and Randomization
* One patient randomized to placebo arm received propranolol. Hence for the per protocol 
analysis, the number of patients in the propranolol and placebo groups are 21 and 22, 
respectively.
Orrey et al. Page 16






















Figure 2. Effect of Propranolol on Overall* Pain Score
*Linear mixed modeling was used to combine pain measurements (waking, worst and least 
pain assessed each day for primary outcome days) for each individual into an overall pain 
score.
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